GlobeNewswire Inc.··NaCompass Therapeutics Delivers Phase 2/3 Data on Tovecimig for Biliary Tract Cancer
Compass Therapeutics to present Phase 2/3 data on tovecimig for biliary tract cancer on April 27, 2026, with 80% overall survival events achieved.
CMPXoncologyimmunotherapy